Welcome, Guest. Please login or register.
May 27, 2022, 12:25:55 pm

Login with username, password and session length

  • Total Members: 36457
  • Latest: vavamas
  • Total Posts: 764597
  • Total Topics: 65095
  • Online Today: 146
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 1
Guests: 103
Total: 104


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Islatravir PrEP Implant Could Prevent HIV for a Year  (Read 1565 times)

0 Members and 1 Guest are viewing this topic.

Online Jim Allen

  • Administrator
  • Member
  • Posts: 18,789
  • Twitter @JimAllenDublin
    • HIV Lessons
Islatravir PrEP Implant Could Prevent HIV for a Year
« on: March 15, 2021, 12:52:33 pm »
Pretty cool results. Looking forward to seeing more development on this one as once a year implant would be very cool.

In Full:

In Short:

Islatravir PrEP Implant Could Prevent HIV for a Year
A next-generation implant maintained adequate drug levels for at least a year in an early study.

An experimental islatravir implant that can be replaced just once a year could one day be a convenient new option for HIV pre-exposure prophylaxis (PrEP), according to early study results presented this week at the virtual Conference on Retroviruses and Opportunistic Infections (CROI).

Formerly known as MK-8591, islatravir is a first-in-class nucleoside reverse transcriptase translocation inhibitor with multiple mechanisms of action. It has a long half-life in the body, suggesting it has the potential to be taken once weekly for HIV treatment or once monthly—or less—for PrEP.

At the 2019 International AIDS Society Conference on HIV Science, Matthews presented the first data from a Phase I clinical trial of a prototype islatravir implant, showing that drug levels remained above the threshold found to be protective in monkeys for at least 12 months.

At CROI, Matthews presented results from a follow-up study of an updated version of the implant. While the older implant contained only islatravir and a polymer that releases small amounts of the drug over time, the next-generation version is easier to manufacture and includes a barium tracer that makes it visible on an X-ray, in case it migrates away from the insertion site. The implant, about the size of a matchstick, is administered using the same applicator as the widely used Nexplanon contraceptive implant.

This study included 36 men and women at low risk for HIV. Twenty-four of them received implants containing 48, 52 or 56 milligrams of islatravir, which were inserted under the skin of the upper arm and left in place for 12 weeks. For each dose level, eight people received islatravir implants and four received matching placebo implants. They were followed for an additional eight weeks after the implants were removed.

Regardless of dose, levels of islatravir triphosphate (the active form of the drug) reached and remained above the target effective threshold for 12 weeks and then began to decline. The highest-dose implant produced protective drug levels for about 16 weeks—four weeks after removal of the implant—while the lower doses fell below the threshold sooner. The researchers projected that the 56-mg implant should release adequate levels of islatravir for almost all individuals for more than 52 weeks. This will offer some forgiveness if replacement is delayed, Matthews said.
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP


Terms of Membership for these forums

© 2022 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.